Chemomab Therapeutics Ltd. Holds Annual Shareholder Meeting

Ticker: CMMB · Form: 6-K · Filed: Jul 1, 2025 · CIK: 1534248

Chemomab Therapeutics LTD. 6-K Filing Summary
FieldDetail
CompanyChemomab Therapeutics LTD. (CMMB)
Form Type6-K
Filed DateJul 1, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: shareholder-meeting, corporate-governance

TL;DR

Chemomab held its shareholder meeting July 1st, nothing major reported.

AI Summary

Chemomab Therapeutics Ltd. held its annual general shareholders meeting on July 1, 2025. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is a pharmaceutical preparations company based in Tel Aviv, Israel. This 6-K filing serves to report the results of this meeting.

Why It Matters

This filing confirms the completion of the annual general meeting, a standard corporate governance event for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine 6-K filing reporting on a shareholder meeting, with no new financial or operational information disclosed.

Key Players & Entities

FAQ

What is the purpose of this 6-K filing?

This 6-K filing is to report the results of Chemomab Therapeutics Ltd.'s annual general shareholders meeting held on July 1, 2025.

When was the annual general shareholders meeting held?

The meeting was held on July 1, 2025, at 4:30 p.m. (Israel time).

Where was the annual general shareholders meeting held?

The meeting was held at Meitar | Law Offices, located at 16 Abba Hillel Road.

What are the former names of Chemomab Therapeutics Ltd.?

Chemomab Therapeutics Ltd. was formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd.

Does Chemomab Therapeutics Ltd. file annual reports under Form 20-F or 40-F?

Chemomab Therapeutics Ltd. files annual reports under cover of Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 1, 2025 regarding Chemomab Therapeutics Ltd. (CMMB).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing